ArticleJournal of pediatric hematology/oncology2019
Prevalence and Clinical Correlations of Somatostatin Receptor-2 (SSTR2) Expression in Neuroblastoma.
Article in Journal of pediatric hematology/oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 33 citations in OpenAlex.
- [EJNMMI research · 2026Article
- Prognostic value of baseline [68Ga]Ga‑DOTA‑NOC PET/CT in paediatric neuroblastoma.European journal of nuclear medicine and molecular imaging · 2026Article
- [European journal of nuclear medicine and molecular imaging · 2026Observational
- Case Report: Evolution of intratumoral spatial heterogeneity assessed by [Frontiers in pediatrics · 2026Article
- [European journal of nuclear medicine and molecular imaging · 2025Article
- Review
- Expanding the therapeutic horizon ofNagoya journal of medical science · 2025Review
- Pathological validation ofScientific reports · 2025Article
- Peptidergic Systems and Neuroblastoma.International journal of molecular sciences · 2025Review
- Theranostics for Neuroblastoma: Making Molecular Radiotherapy Work Better.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Application of modified Curie and SIOPEN skeleton scoring systems inAnnals of nuclear medicine · 2025Article
- Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors.Journal of neuroendocrinology · 2025Review
- Octreotide attenuates intestinal barrier damage by maintaining basal autophagy in Caco2 cells.Molecular medicine reports · 2024Article
- Heterogeneous SSTR2 target expression and a novelFrontiers in oncology · 2024Article
- Novel Meta-iodobenzylguanidine and Etoposide Complex: Physicochemical Characterization and Mathematical Modeling of Anticancer Activity.AAPS PharmSciTech · 2023Article
- Imaging of pediatric neuroblastoma: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper.Pediatric blood & cancer · 2023Article
- Comprehensive Assessment of Somatostatin Receptors in Various Neoplasms: A Systematic Review.Pharmaceutics · 2022Review
- A Phase II Trial of a Personalized, Dose-Intense Administration Schedule ofFrontiers in pediatrics · 2022Article
- The cyclin dependent kinase inhibitor p21Frontiers in oncology · 2022Article
- p53-Mediated Radiosensitization ofBiomolecules · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Alternative radiolabeled, targeted agents are being investigated for children with relapsed neuroblastoma (NB) who do not respond to I-metaiodobenzylguanidine (MIBG) therapy. (DOTA-Tyr)-octreotate targets somatostatin receptors (SSTRs), particularly SSTR2, which are expressed on NB cells. We investigated SSTR2 expression in NB tumors (36 high-risk [HR]; 33 non-HR patients) and correlated SSTR2 levels with clinical features, norepinephrine transporter (NET) expression, and MIBG avidity. SSTR2 and NET immunohistochemistry scores (0 to 3) were calculated on biopsies using digital image analysis based on staining intensity and distribution. Clinical data were correlated with SSTR2 expression. Median SSTR2 score for 69 patients was 1.31 (0.26 to 2.55). Non-HR NB was associated with a higher SSTR2 score (P=0.032). The SSTR2 expression did not correlate with age, International Neuroblastoma Staging System (INSS) stage, MYCN amplification and histology. Higher SSTR2 scores were observed in MIBG-avid versus MIBG-nonavid NB. SSTR2 score was not significantly associated with NET score (r=-0.062, P=0.62). Twenty-six patients who relapsed or progressed had a median SSTR2 score of 1.33 (0.26 to 2.55). Patients with NB including relapsed or progressive disease showed SSTR2 expression at diagnosis, suggesting they could be candidates for radiolabeled-DOTA-conjugated peptide imaging or therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.